<DOC>
	<DOCNO>NCT00845923</DOCNO>
	<brief_summary>This proof concept study design evaluate safety efficacy topically administer Civamide Patch treatment moderate severe daily pain associate postherpetic neuralgia localize trunk , localize post-incisional neuropathic pain syndrome trunk .</brief_summary>
	<brief_title>Evaluation Civamide Patch Treatment Postherpetic Neuralgia Post-Incisional Neuralgia</brief_title>
	<detailed_description>There approximately 20 evaluable subject open-label study . The study compose 1-week non-treatment Baseline Period ( Day -7 -1 ) , subject require complete Daily Diary assess overall pain sleep interference . The 1-week Baseline Period follow 4-week Treatment Period , subject apply Civamide Patch ( 0.015 % ) daily 12 hour per day , period 4 week , complete Daily Diary assess overall pain sleep interference , follow 2-week Post-Treatment Observation Period . In course study , subject visit clinic total five time physical examination , vital sign , review diary , distribution collection test patch . Efficacy assessment mean change Baseline Period efficacy variable course study .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Neuralgia , Postherpetic</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Subject healthy history postherpetic neuralgia least 6 month heal herpes zoster skin rash . Subject must take stable dose medication ( ) PHN pain , expect remain stable daily dose throughout study . Single , localize area skin trunk PHN , measure approximately 10 x 14 cm less . Average Daily Pain Score 4 high 11point Likert scale 7Day Baseline Period . Males females 18 80 year age , inclusive . Nonpregnant , nonlactating female childbearing potential agree use medically acceptable form birth control throughout study female nonchildbearing potential . Negative urine pregnancy test must confirm Screening . Subject agree begin new concomitant medication study . Subject area skin trunk affect PHN , great area amendable treatment patch , exhibit active skin disease , infection , severe erythema , compromise integrity skin , could influence interfere evaluation safety efficacy . Subject history frequent headache painful condition ( associate PHN ) , expect require twice week additional administration OTC acetaminophen ( ≤ 1000 mg total daily dose pain management ) . Clinical , historical previous laboratory evidence significant cardiovascular , renal , gastrointestinal , pulmonary , hepatic , endocrine , neurological , psychological , systemic disease might confound result study pose additional risk subject . Subject immunocompromised . Use restrict medication within give time period prior Baseline Period throughout study ( See Table 1 ) . Females pregnant , breastfeeding , plan become pregnant study . Subject history alcohol and/or drug abuse within past year . Subject previously participate Civamide study . Subject participate another investigational study , take another investigational drug within past 4 week . Subject receive neurolytic neurosurgical therapy previous episode postherpetic neuralgia . Known hypersensitivity contraindication use Civamide ( zucapsaicin ) , capsaicin ( Zostrix® , ZostrixHP® , Axsain® , related product ) excipients clinical formulation . If , reason subject deem suitable Investigator , enrol . Initiation medication , discontinuation medication change regimen exist medication ( ) therapies less required period stable dose prior enter Baseline Period . Topical use moisturizer similar product near treatment area within 48 hour Day 1 completion Study Day 43 . Topical use capsaicincontaining product 60 day prior Day 1 completion Study Day 43 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Postherpetic neuralgia least 6 month</keyword>
</DOC>